Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?

Singh, Saumya; Fereshetyan, Katarine; Shorter, Susan; Paliokha, Ruslan; Dremencov, Eliyahu; Yenkoyan, Konstantin; Ovsepian, Saak V.

doi:10.1016/j.drudis.2022.103467

Cited by 14 publications

(9 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The occurrence of PPD during a six-month period was shown to be linked to elevated levels of CRP and IL-6 in the blood upon admission [31], indicating that general in ammation is a predictive marker for PPD. Additionally, BDNF lack is a vital factor in perinatal depression [32]. The plasma level of BDNF was shown to be signi cantly lower in the group of individuals experiencing PPD compared to the group without depressive symptoms six weeks after delivery [33].…”

Section: Discussionmentioning

confidence: 99%

Effect of esketamine on postpartum depression and pain control after caesarean section: A randomized, double-blind, controlled clinical trial

Li,

Zhuo,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Postpartum depression (PPD) after cesarean delivery is a common complication. Esketamine's effects on PPD in women undergoing cesarean section remain contradictory, despite ketamine's prophylactic effects. This study evaluated the effect of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) to prevent PPD in women undergoing caesarean section. Methods A total of 275 parturients scheduled for caesarean section and subsequent PCIA were recruited from a single centre and randomised to control (sufentanil 2 µg/kg + tropisetron 10 mg) or esketamine (additional esketamine 1.5 mg/kg). The primary outcome was the incidence of PPD, as measured by the Edinburgh postnatal depression scale (EPDS), following surgery. Secondary outcomes were cumulative sufentanil consumption, numerical rating scale (NRS) scores, stress hormone levels and biomarkers of PPD. Results A total of 246 postpartum women with caesarean delivery were included in the final analysis. The incidence of depression among parturients on postoperative day 42 was higher in the control group compared to the esketamine group, with rates of 17.6% and 8.2% respectively (P = 0.02). The EPDS scores were significantly higher in the control group, with a mean score of 9.02 ± 2.21 vs. 6.87 ± 2.14 in the esketamine group (p < 0.0001). Sufentanil consumption was significantly lower in the esketamine group in the 0–24 h (42.5 ± 4.58 µg vs 50.15 ± 5.47 µg, P = 0.04) and 0–48 h (87.40 ± 9.51 µg vs 95.10 ± 9.36 µg, P = 0.04) postoperative periods compared to the control group. Significant differences in movement were observed between the two groups at 24 and 48 hours after cesarean section (3.39 ± 1.57 vs 4.50 ± 0.80, P = 0.02; 2.43 ± 0.87 vs 3.56 ± 0.76, P = 0.02). Furthermore, the plasma level of stress hormone was significantly lower on postoperative day 3 in the esketamine group compared to the control group. The frequency of side effects observed in both groups was comparable. Conclusions Esketamine (1.5 mg/kg) used as a supplement in PCIA significantly decreases the occurrence of PPD in 42 days and reduced cumulative sufentanil consumption in a span of 48 hours post-cesarean operation, without raising the rate of adverse effects. Trial registration: Registered in the Chinese Clinical Trial Registry (ChiCTR2200067054) on December 26, 2022.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of esketamine on postpartum depression and pain control after caesarean section: A randomized, double-blind, controlled clinical trial

Li,

Zhuo,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Second, activation of delta-opioid receptors may affect the expression of certain maternal neurotrophic factors, such as BDNF ( Torregrossa et al, 2006 ). Maternal neurotrophins are in turn suggested to interact with the embryonal ones and to affect developmental and functioning of the embryonal brain ( Singh et al, 2022 ). Finally, delta agonists can affect the maternal care behavior that may influence offspring behavior and neurophysiology ( Gemmel et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Maternal treatment with a selective delta-opioid receptor agonist during gestation has a sex-specific pro-cognitive action in offspring: mechanisms involved

Dremencov,

Oravcova,

Grinchii

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Background: There is growing evidence that the treatment of several mental disorders can potentially benefit from activation of delta-opioid receptors. In the future, delta-agonists with a safe pharmacological profile can be used for the treatment of mood disorders in pregnant women. However, the data on prenatal exposure to delta-opioid agonists are missing. The present study is aimed to test the hypothesis that the activation of delta-opioid receptors during gravidity has positive effects on the behaviour accompanied by changes in glutamate and monoamine neurotransmission.Methods: Gestating Wistar rats were chronically treated with a selective delta-agonist SNC80 or vehicle. Adult male and female offspring underwent novel object recognition (for the assessment of cognition) and open field (for the assessment of anxiety and habituation) tests, followed by in vivo electrophysiological examination of the activity of hippocampal glutamate and midbrain serotonin (5-HT) and dopamine neurons.Results: We found that the maternal treatment with SNC80 did not affect the offspring’s anxiety, habituation, and 5-HT neuronal firing activity. Female offspring of SNC80-treated dams exhibited improved novelty recognition associated with decreased firing rate and burst activity of glutamate and dopamine neurons.Conclusion: Maternal treatment with delta-opioid agonists during gestation may have a pro-cognitive effect on offspring without any negative effects on anxiety and habituation. The putative pro-cognitive effect might be mediated via mechanism(s) involving the firing activity of hippocampal glutamate and mesolimbic dopamine neurons.

show abstract

“…BDNF is broadly distributed throughout the brain, including the cerebral cortex and hippocampus ( Kumar and Singh, 2016 ; Kumar and Singh, 2018 ; Kumar et al, 2022 ). It influences the release of neurotransmitters and trophic factors and encourages the differentiation and regeneration of injured neurons ( Singh et al, 2023 ; Vyas et al, 2023 ). According to earlier research, BNDF is essential for preserving and fostering nerve fiber regeneration in monkey stroke models.…”

Section: Discussionmentioning

confidence: 99%

Effects and safety of Ginkgo biloba on depression: a systematic review and meta-analysis

Lin,

Sun,

Yang

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Because depression is a major factor contributing to the global disease burden, we tried to analyze the effects and safety of Ginkgo biloba (GKB) on patients with depression.Methods: We conducted a literature search for articles published between January 2002 and May 2022 in seven online databases (PubMed, Scopus, Embase, Google Scholar, Web of Sciences, Cochrane Library, and China National Knowledge Infrastructure). A systematic literature review and meta-analysis were performed to compare the effects and safety of GKB on patients with depression, including subjective and objective indicators of depression evaluation.Results: In total, 21 eligible articles with nine indicators among 2074 patients were included. Several outcomes showed a difference, and the GKB group had better results than the control group, including the Hamilton Depression Scale (HAMD), after taking GKB for 4 weeks (MD = −2.86, 95%CI [−4.27, −1.46], p < 0.01), 6 weeks (mean difference (MD) = −3.36, 95%CI [−4.05, −2.67], p < 0.01), and 8 weeks (MD = −4.58, 95% CI [−6.11, −3.05], p < 0.01), modified Barthel index (MBI) (MD = 14.86, 95%CI [12.07, 17.64], p < 0.01), modified Edinburgh-Scandinavian stroke scale (MESSS) (MD = −4.57, 95%CI [−6.34, −2.79], p < 0.01), brain-derived neurotrophic factor (BDNF) (MD = 16.35, 95%CI [7.34, 25.36], p < 0.01), 5-hydroxytryptamine (5-HT) (MD = 4.57, 95%CI [3.08, 6.05], p < 0.01), and clinical efficacy (risk ratio, RR = 1.24, 95%CI [1.17, 1.32], p < 0.01). However, there were no differences in adverse events between GKB and controls.Conclusion: In conclusion, the main finding was that patients treated with GKB had better MBI, MESSS, BDNF, 5-HT, and HAMD values after 4 weeks, 6 weeks, and 8 weeks than the control group. GKB might reduce the risk of depression or depressive symptoms with safe clinical efficacy.Systematic Review Registration: identifier (INPLASY2023100052)

show abstract

Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?

Cited by 14 publications

References 71 publications

Effect of esketamine on postpartum depression and pain control after caesarean section: A randomized, double-blind, controlled clinical trial

Effect of esketamine on postpartum depression and pain control after caesarean section: A randomized, double-blind, controlled clinical trial

Maternal treatment with a selective delta-opioid receptor agonist during gestation has a sex-specific pro-cognitive action in offspring: mechanisms involved

Effects and safety of Ginkgo biloba on depression: a systematic review and meta-analysis

Contact Info

Product

Resources

About